Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Acute 3Sarcoma 2Rhabdomyosarcoma 2Myelodysplastic Syndromes 2Leukemia, Biphenotypic, Acute 2Ganglioneuroblastoma 2Sarcoma, Myeloid 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Neuroblastoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Malignant mesenchymal tumor 1Lymphoma, Large B-Cell, Diffuse 1Localized Extraskeletal Ewing Sarcoma 1Leukemia 1Heart Failure 1Drug-Related Side Effects and Adverse Reactions 1Dendritic Cell Sarcoma, Interdigitating 1Degradation of Top2b and Top2a in Human by Dexrazoxane 1Cardiotoxicity 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Standard of Care 2Rituximab 2Carvedilol 2sacubitril and valsartan sodium hydrate drug combination 1pegfilgrastim 1obinutuzumab 1empagliflozin 1dapagliflozin 1acalabrutinib 1Vincristine 1Vascular Stiffness 1Valsartan 1Specimen Handling 1Pulse Wave Analysis 1Prednisolone 1Practice Guidelines as Topic 1Palliative Care 1Nutrition Assessment 1Mesenchymal Stem Cell Transplantation 1Lenalidomide 1Health Information Exchange 1Exercise 1Eplerenone 1Electronic Health Records 1Electrocardiography 1Echocardiography 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Heart Failure × Dexrazoxane × 1 year × Clear all
NCT06220032 2026-01-05

HO170DLBCL

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 3 Recruiting
324 enrolled
LymphoidSarcoma

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡